Introduction: In pituitary tumors markers of proliferation and progression essential for
Introduction
Following the 2004 WHO (World Health Organization) classification of pituitary tumors [1] [2] [3] [4] where the concept of atypical adenoma was introduced, the Ki-67 antigen and p53 immunoreactivity are among the most frequently evaluated markers in pituitary adenomas.
The new prognostic clinico-pathological classification of pituitary adenomas proposed by Trouillas et al. [5] also uses these markers of cell cycle for tumor grading.
The Ki-67 antigen, present in all active phases of mitosis, is absent in the G 0 phase. A high Ki-67 index correlates well with tumor invasiveness and its recurrence following surgical treatment [6, 7] , however, low Ki-67 indices, comparable with those typical of non-invasive tumors, are quite frequently observed in aggressively progressing adenomas [8, 9] .
Despite considerable progress in understanding the pathogenesis of pituitary adenomas, no single marker has been found to predict aggressive behavior of pituitary adenomas independently. Therefore other specific markers of pituitary adenoma proliferation and angiogenesis, including microRNAs, are under investigation [10, 11] .
Topoisomerase 2 alpha (Topo2A) has been established as one of the key enzymes in DNA replication and cell division [12] indicating cell proliferation activity in many tumors.
Topo2A is also the target for several cytostatic drugs [13, 14] .
Determination of Topo2A activity enabled the group of invasive pituitary adenomas to be distinguished [15, 16] . In pituitary adenomas, Wolfsberg et al. [17] found a strong correlation between MIB-1 and Topo2A expression.
The aim of our work was to investigate whether topoisomerase 2 alpha expression (as based on immunohistochemical staining) could serve as a prognostic factor in the treatment of patients with pituitary adenoma. In our study we investigated retrospectively the correlation of Topo2A labelling index (LI) with demographic, clinical and imaging data of these patients.
Materials and methods
A group of 60 patients with pituitary adenoma, (patient characteristics - Table 1 (Table 1) .
The study was approved by the Bioethical Committee of the Jagiellonian University Medical College.
Fundus abnormalities and visual field defects were assessed retrospectively from patients' medical records.
Tumor size, defined as its largest dimension, sella turcica destruction, penetration into cavernous or sphenoid sinus, optic chiasm compression (Table 1) were evaluated from 1.5 T MR images obtained prior to, and 3-6, 12, 24, 36 and 48 months following surgery. Routine T1-weighted spin-echo sequences, before and after administration of 0.1 mmol gadolinium chelate were obtained. All MR images were evaluated by the same radiologist.
Tumor invasiveness was assessed according to radiological criteria of Knosp et al. [18] and Zada et al. [19] and from surgeon's descriptions in the patient records. Tumor recurrence/progression was defined as regrowth (enlargement) of residual pituitary adenoma after surgery.
Patients with prolactinoma who required pharmacological treatment (6/13) received dopamine agonist (bromocriptine) for 3-6 months. Patients with acromegaly (8/16) were treated with somatostatin analogue (octreotide LAR) 6-12 months prior to surgery. Patients with pituitary insufficiency received appropriate hormone replacement. Prior to surgery no patient was diagnosed with diabetes insipidus. Recurrence of hormonal secretion was considered in patients who did not fulfil generally accepted criteria of cure after surgery [20] [21] [22] [23] . In Kaplan-Meier graphs, time-to-incidence was plotted, with 48 months as the last observation period. For Kaplan-Meier and ROC (Receiver Operating Characteristic) plots statistic tests were generated using GraphPad Prism version 5.03 for Windows (GraphPad Software, San Diego CA, USA).
To establish predictors of recurrence and pituitary tumor advancement Cox multiple regression and logistic regression statistic tests were generated using the Statsdirect version 2.0 for Windows (Statsdirect Ltd., Cheshire, UK). The level of statistical significance used in this study was P ≤0.05. Applying Kaplan-Meier plots for groups of patients in whom values of Topo2A index were 1% or less, and those in whom this value exceeded 1%, significantly higher frequency of MRI-confirmed tumor recurrence was observed in the last group of patients (P<0.001) ( Figure 4A ). The same rule was found to apply in the case of patients with hormone immunonegative adenomas (P<0.01) ( Figure 4B ).
Results

Occurrence
The relative risk (RR) of tumor recurrence in patients with expression of Topo2A is not statistically significant. However, for patients with Topo2A expression >1%, RR = 3.5 (95%CI: 1.8-6.9), p<0.001, i.e., the relative risk of tumor recurrence is 3.5 times higher.
Following Cox's multiple regression analysis, only Topo2A expression >1% remained as an independent predictor of MRI-confirmed tumor recurrence or progression (Table 2) 
Discussion
In our study we investigated Topoisomerase 2 alpha as a proliferation marker in pituitary tumors of patients who underwent neurosurgery. We evaluated the relationship between
Topo2A labelling index and demographic data and tumor features in the studied patients in order to establish its prognostic value to predict tumor invasiveness. We compared Topo2A expression against tumor progression/recurrence as indication for reoperation or radiotherapy.
We also analyzed the effect on the Topo2A index of preoperative treatment with somatostatin analogues in acromegaly patients, or of dopaminergic agonists in prolactinoma patients. So far, no prognostic advantage of Topo2A over Ki-67 has been shown [16, 17, 24] .
Pituitary tumors are usually benign and grow slowly, presenting no clinical manifestations, as evidenced by the disparity between the number of symptomatic adenomas against their number established on autopsy [25] . Local invasion and infiltration of adjacent structures, post-operative regrowth or persistence of hormonal function are potential indicators of aggressiveness [26] [27] [28] [29] . In order to treat patients more effectively, rather than to await confirmation of tumor recurrence by MR imaging, suitable markers of invasiveness and proliferation of pituitary adenomas are sought to select patients with atypical pituitary adenomas. In our group of 60 patients, 73% expressed Topo2A, against 76%, reported by Vidal et al. [16] .
In agreement with Suzuki et al. [15] and Wolfsberger et al. [17] , we found that Topo2A expression did not depend on age of our patients. However, Wolfsberger et al. [17] found that female gender is significantly associated with higher Topo2A index. Vidal et al. [16] found a negative correlation between Topo2A expression and patient age.
However, our patient group differs from those of the above authors, in the number of patients and the spectrum of adenomas analyzed.
In our study the expression of Topo2A was higher in macroadenomas and correlated with tumor size, in agreement with Suzuki et al. [15] . Wolfsberger et al. [17] found no dependence of Topo2A expression on tumor size, while Vidal et al. [16] suggested a negative correlation.
In hormone immunonegative adenomas, we found Topo2A expression to be higher, compared with other tumors. In particular, we observed high Topo2A indices in large adenomas compressing the optic chiasm and penetrating the cavernous sinus. Basing on results of MRI and hormonal tests, one may conclude that high values of Topo2A indices were seen predominantly in macroadenomas with no hormonal function.
Our results concur with those of Saeger et al. [24] who evaluated the expression of Ki-67, Topo2A i Cyclin D 3 as proliferation markers in hormonally non-functioning pituitary adenomas.
In studies, of Vidal et al. [16] or Wolfsberger et al. [17] involving larger groups of patients, highest values of Topo2A expression were observed in pituitary carcinomas, silent-ACTH adenomas, prolactinomas, somatotropinomas, and silent subtype 3 adenomas.
Our results differ from those cited above. The large dispersion of Topo2A index values found in our relatively small group of patients with diverse types of pituitary adenoma and no pituitary carcinoma cases may have affected the results of our statistical analysis.
We found the evaluation of visual field to be a significant clinical indicator of pituitary tumor invasiveness, correlating with Topo2A expression. Visual field impairment was observed in 65 % of our macroadenoma patients, this being consistent with the correlation between Topo2A expression and tumor size. Visual field impairment in up to 74% of adenoma patients was stated by Thomas et al. [30] .
Tumor recurrence or progression in patients undergoing transsphenoidal surgery is reported to occur in 30.8% [6] up to 46% [27] cases. Over a four-year period we observed recurrence or tumor progression in 36.7% of cases, as based on MRI, most likely due to large tumor sizes and to non-radical surgery.
We found significantly higher Topo2A expression in patients with tumor recurrence or progression, indicating that the predictive factor of tumor regrowth is represented by a high value of Topo2A index rather than by Topo2A expression only. While no markers for increased risk of recurrence have so far been established, our novel result is that Topo2A labelling index exceeding 1% predicts pituitary adenoma regrowth. From multiple regression analysis, we found Topo2A index greater than 1% to be an independent predictor of MRIconfirmed tumor recurrence or progression.
Thus, from our finding, patients in whom Topo2A index greater than 1% is stated, being at a higher risk of tumor recurrence, should be monitored more frequently and qualified for radiotherapy early.
Concurring with Suzuki et al. [15] and Vidal et al. [16] , we have shown higher Topo2A index values in tumors which compress or infiltrate the sella turcica and cavernous sinus, than in tumors without such features.
Pre-operative treatment with somatostatin analogues in acromegaly patients results in a statistically significant decrease in Topo2A expression. Somatostatin receptors are not expressed exclusively in the pituitary cells. They are targeted for diagnostics and therapy in many diseases [31, 32] . Application of somatostatin analogues, apart from achieving tumor shrinkage and better metabolic balance, also improves the efficiency of neurosurgery [33] [34] [35] .
Low values of the Topo2A index in our patients treated with octreotide provide evidence, at the molecular level, of their effectiveness in controlling GH-producing adenomas. Vidal et al. limited [36] [37] [38] . In our study, these tumors showed the highest values of Topo2A expression and a high recurrence rate.
It is worth noting that somatostatin analogues and dopamine agonists have been shown to be efficient in some 12% and 27.6% of patients, respectively, in non-functioning pituitary adenomas, as summarized by Colao et al. [39] . We have shown this treatment to effectively decrease Topo2A expression. However, insufficient evidence-based data so far preclude any clear recommendation that somatostatin analogues and dopamine agonists be applied in treating non-functioning pituitary adenomas.
Analysis of the results of immunocytochemistry and understanding subcellular mechanism that underlie pituitary tumor development will allow new tumor aggression markers and novel targeted therapies to be established.
Conclusions
1. Topo2A labelling index exceeding 1% was found to be a prognostic factor for recurrence/progression of tumors, especially in hormonally inactive adenomas.
2. Expression of Topo2A correlates with tumor size and degree of its invasiveness or of compression of anatomical structures around the sella turcica and may constitute a marker which enables patients with potentially aggressive pituitary adenomas to be selected for further therapy.
3.
Use of somatostatin analogues in acromegaly patients inhibits the expression of Topo2A, providing molecular evidence of the effectiveness of these analogues.
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